- Home
- NTLA
as of 01-08-2026 3:58pm EST
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 986.9M | IPO Year: | 2016 |
| Target Price: | $19.83 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.90 - $28.25 | Next Earning Date: | 02-26-2026 |
| Revenue: | $57,528,000 | Revenue Growth: | 33.52% |
| Revenue Growth (this year): | 1.96% | Revenue Growth (next year): | -7.06% |
AI-Powered NTLA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Intellia Therapeutics Inc. (NTLA)
Director
Avg Cost/Share
$9.35
Shares
150,000
Total Value
$1,402,500.00
Owned After
207,453
SEC Form 4
EVP, Chief Financial Officer
Avg Cost/Share
$9.21
Shares
6,379
Total Value
$58,750.59
Owned After
99,683
SEC Form 4
EVP, General Counsel
Avg Cost/Share
$9.21
Shares
10,397
Total Value
$95,756.37
Owned After
101,528
SEC Form 4
President and CEO
Avg Cost/Share
$9.21
Shares
34,146
Total Value
$314,484.66
Owned After
1,013,339
SEC Form 4
EVP, Chief Medical Officer
Avg Cost/Share
$9.21
Shares
11,903
Total Value
$109,626.63
Owned After
121,249
SEC Form 4
EVP, Chief Technical Officer
Avg Cost/Share
$9.21
Shares
9,515
Total Value
$87,633.15
Owned After
87,118
SEC Form 4
VP, Chief Accounting Officer
Avg Cost/Share
$9.21
Shares
2,989
Total Value
$27,528.69
Owned After
52,277
SEC Form 4
EVP, Chief Scientific Officer
Avg Cost/Share
$9.21
Shares
8,508
Total Value
$78,358.68
Owned After
98,533
SEC Form 4
President and CEO
Avg Cost/Share
$9.52
Shares
88,146
Total Value
$836,384.40
Owned After
1,013,339
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Fred E | NTLA | Director | Jan 5, 2026 | Buy | $9.35 | 150,000 | $1,402,500.00 | 207,453 | |
| Dulac Edward J III | NTLA | EVP, Chief Financial Officer | Jan 5, 2026 | Sell | $9.21 | 6,379 | $58,750.59 | 99,683 | |
| BASTA JAMES | NTLA | EVP, General Counsel | Jan 5, 2026 | Sell | $9.21 | 10,397 | $95,756.37 | 101,528 | |
| LEONARD JOHN M | NTLA | President and CEO | Jan 5, 2026 | Sell | $9.21 | 34,146 | $314,484.66 | 1,013,339 | |
| Lebwohl David | NTLA | EVP, Chief Medical Officer | Jan 5, 2026 | Sell | $9.21 | 11,903 | $109,626.63 | 121,249 | |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Jan 5, 2026 | Sell | $9.21 | 9,515 | $87,633.15 | 87,118 | |
| Dube Michael P | NTLA | VP, Chief Accounting Officer | Jan 5, 2026 | Sell | $9.21 | 2,989 | $27,528.69 | 52,277 | |
| Schultes Birgit C | NTLA | EVP, Chief Scientific Officer | Jan 5, 2026 | Sell | $9.21 | 8,508 | $78,358.68 | 98,533 | |
| LEONARD JOHN M | NTLA | President and CEO | Dec 11, 2025 | Sell | $9.52 | 88,146 | $836,384.40 | 1,013,339 |
Compare NTLA vs Leading Stocks
See how NTLA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTLA Intellia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.